News
Novo Nordisk’s CagriSema Falls Short of 25% Weight Loss Target in Patients with Obesity or Overweight
Results from the Phase III REDEFINE 1 trial show that CagriSema led to a 22.7% mean weight reduction at 68 weeks in adults with overweight or obesity and a weight-related medical condition, but without diabetes.
Head-splitting migraines could be the next ailment in a seemingly endless list that a class of blockbuster weight-loss drugs ...
The term sheet was signed in the presence of senior officials from BIRAC, the department of biotechnology, and industry ...
Amgen’s monthly obesity candidate led to substantial weight loss but a high rate of side effects and discontinuations in a ...
On June 19, 2025 The Globe and Mail hosted an event where experts discussed how treating obesity as a chronic disease can ...
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg ...
The Wegovy maker says the telehealth company didn't stop selling compounded versions of the blockbuster drug after Novo ...
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
An obesity drug from China helped patients lose a lot of weight in a late-stage clinical trial, making it a prospective new ...
Participants with obesity (obesity cohort) were randomly assigned in a 3:3:3:2:2:2:3 ratio to receive maridebart cafraglutide subcutaneously at a dose of 140, 280, or 420 mg every 4 weeks without ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback